Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expression of SREBF2 and HMGCR discriminates the viability of steatotic grafts for human liver transplantation

  • Baulies, Anna
  • Torres, Sandra
  • Fucho, Raquel|||0000-0002-1774-9099
  • Núñez Pereira, Susana
  • Torres, Ferran|||0000-0002-7355-7913
  • Ferrer-Fàbrega, Joana
  • Díaz, Alba|||0000-0002-0456-7085
  • Rico, Naira
  • García-Valdecasas, Juan Carlos
  • Fuster, Josep
  • Adàlia, Ramon|||0009-0004-9458-1922
  • Paredes, David
  • Rimola, Antoni
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
Hepatic steatosis presents a rising challenge in liver transplantation (LT), yet the precise underlying players remain incompletely understood. As steatosis reflects the accumulation of several types of lipids, including cholesterol, which has emerged as a key player in metabolic-dysfunction associated fatty liver disease, we aimed to characterize the content of lipids and the expression of cholesterol metabolic genes in liver biopsies before (pre-LT) and after LT (post-LT), with the ultimate goal of identifying factors that may impact graft loss and the overall outcomes of LT. Lipid content and cholesterol-related genes in pre- and post-LT graft biopsies, clinical outcome, and survival within the first year after LT were analyzed in 174 patients. Unlike free fatty acids (FFA) and triglycerides, total and free cholesterol (FC) levels are maintained in pre- and post-LT samples. Increased FC and FFA levels in pre-LT samples were associated with early allograft dysfunction (EAD). The increase in the expression of cholesterol regulatory genes SREBF2 and HMGCR in pre-LT samples was identified as a potential risk factor of death after LT, particularly with SREBF2, whose expression is associated with EAD and graft loss (GL). Collectively, these data link the expression of genes involved in the synthesis of cholesterol to LT-related mortality. These findings may translate to an increased application of marginal steatotic grafts in LT, thereby promoting a safe outcome.
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

  • Matilla-Cabello, Gonzalo
  • Remesal-Doblado, Ángela
  • Celebi-Cinar, Muzzez
  • Bodoque-García, Ana
  • Betul Metin, Fatma
  • Rezaei, Aida
  • Aftab, Moiz
  • De los Santos-Fernández, Romina
  • Segovia-Zafra, Antonio
  • Álvarez-Álvarez, Ismael
  • Andrade-Bellido, Raúl Jesús
  • Cakan-Akdogan, Gulcin
  • Lucena-González, María Isabel
  • Konu, Ozlen
  • Villanueva-Paz, Marina
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics., Consejería de Salud de Andalucía, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Agencia Española del Medicamento y Productos Sanitarios, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, Universidad de Málaga
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

  • Ruiz-Malagón, Antonio J.
  • Herraiz-Vilela, Marina
  • Pinazo-Bandera, José
  • Toro-Ortiz, Juan Pedro
  • López-Gómez, Carlos
  • Ho-Plagaro, Ailec
  • Garrido-Sánchez, Lourdes
  • Robles-Díaz, María Mercedes
  • Taminiau, Bernard
  • Daube, Georges
  • Sanabria-Cabrera, Judith
  • Matilla-Cabello, Gonzalo
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • García-Fuentes, Eduardo
  • García-Cortés, Miren
  • Rodríguez-Díaz, Cristina
The role of extracellular vesicles secreted by the gut microbiota present in faeces (fEVs) is not well known in metabolic dysfunction- associated steatotic liver disease (MASLD) and idiosyncratic drug-induced liver injury (DILI). We identify the microbiome profiles of fEVs in these liver diseases, and analyse the effects of fEVs from MASLD, without (F ≤ 2) or with (F ≥ 3) significant liver fibrosis, and DILI patients on inflammation, steatosis and mitochondrial function. DILI patients showed a consistent pattern in fEVs, characterised by a decrease in Paraprevotella and an increase in AAP99, Acinetobacter, Actinobacillus, Aerococcus and Anaeroglobus . A higher presence of 16S rDNA was observed in plasma EVs from MASLD and DILI patients. HepG2 cells treated with DILI and MASLD F ≥ 3 fEVs increased TLR4 , TLR5 , IL6 and CASP3 expression, and accumulation of lipid droplets. DILI fEVs enhanced the hepatotoxic impact of diclofenac on the response to microbial components ( TLR4 , TLR5 ), inflammatory response ( IL1B , IL6 ), accumulation of lipid droplets and mitochondrial dysfunction ( OPA1 , DNM1L ). In conclusion, bacterial EVs enter the bloodstream and could modulate the immune response. DILI and MASLD F ≥ 3 fEVs are drivers of the pro-inflammatory response and hepatocyte steatosis. DILI fEVs have a distinct bacterial profile that enhances the hepatotoxic potential of diclofenac., Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Consejería de Salud, Junta de Andalucía, European Comission, Ministerio de Ciencia, Innovación y Universidades
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Ayuso García, Paula
  • Varela Rey, Marta María
  • Woodhoo, Ashwin
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs’ commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis

  • Alarcón-Vila, Cristina
  • Insausti, Naroa
  • Torres, Sandra
  • Segalés, Paula
  • Conde de la Rosa, Laura
  • Nuñez, Susana
  • Fucho, Raquel
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
Alcoholic (ASH) and nonalcoholic. (NASH).steatohepatitis are advanced.stages.of.fatty.liver.disease.Methionine adenosyltransferase 1A (MAT1A) plays a key role in hepatic methionine metabolism and germline Mat1a deletion in mice promotes NASH. Acid sphingomyelinase (ASMase) triggers hepatocellular apoptosis and liver fibrosis and has been shown to downregulate MAT1A expression in the context of fulminant liver failure. Given the role of ASMase in steatohepatitis development, we investigated the status of ASMase in Mat1a-/- mice and the regulation of ASMase by SAM/SAH. Consistent with its role in NASH, Mat1a-/- mice fed a choline-deficient (CD) diet exhibited macrosteatosis, inflammation, fibrosis and liver injury as well as reduced total and mitochondrial GSH levels. Our data uncovered an increased basal expression and activity of ASMase but not neutral SMase in Mat1a-/- mice, which further increased upon CD feeding. Interestingly, adenovirus-mediated shRNA expression targeting ASMase reduced ASMase activity and protected Mat1a-/- mice against CD diet-induced NASH. Similar results were observed in CD fed Mat1a-/- mice by pharmacological inhibition of ASMase with amitriptyline. Moreover, Mat1a/ASMase double knockout mice were resistant to CD-induced NASH. ASMase knockdown protected wild type mice against NASH induced by feeding a diet deficient in methionine and choline. Furthermore, Mat1a-/- mice developed acute-on-chronic ASH and this outcome was ameliorated by amitriptyline treatment. In vitro data in primary mouse hepatocytes revealed that decreased SAM/SAH ratio increased ASMase mRNA level and activity. MAT1A and ASMase mRNA levels exhibited an inverse correlation in liver samples from patients with ASH and NASH. Thus, disruption of methionine metabolism sensitizes to steatohepatitis by ASMase activation via decreased SAM/SAH. These findings imply that MAT1A deletion and ASMase activation engage in a self-sustained loop of relevance for steatohepatitis., This project has received funding from the European Horizon’s research and innovation programme HORIZON-HLTH-2022- STAYHLTH-02 under agreement No 101095679. We acknowledge the support from grants PID2019-111669RB, and PID2020-115055RB-I00 from Plan Nacional de I + D funded by the Agencia Estatal de Investigacion ´ (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017-1112, European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, the “ER stress-mitochondrial cholesterol axis in obesity-associated insulin resistance and comorbidities”-Ayudas FUNDACION BBVA, the Red Nacional 2018-102799-T de Enfermedades Metabolicas ´ y Cancer ´ and the Project 201916/31 Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundacio ´ Marato TV3.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial cholesterol: Metabolism and impact on redox biology and disease

  • Goicoechea, Leire
  • Torres, Sandra
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Cholesterol is a crucial component of membrane bilayers by regulating their structural and functional properties. Cholesterol traffics to different cellular compartments including mitochondria, whose cholesterol content is low compared to other cell membranes. Despite the limited availability of cholesterol in the inner mitochondrial membrane (IMM), the metabolism of cholesterol in the IMM plays important physiological roles, acting as the precursor for the synthesis of steroid hormones and neurosteroids in steroidogenic tissues and specific neurons, respectively, or the synthesis of bile acids through an alternative pathway in the liver. Accumulation of cholesterol in mitochondria above physiological levels has a negative impact on mitochondrial function through several mechanisms, including the limitation of crucial antioxidant defenses, such as the glutathione redox cycle, increased generation of reactive oxygen species and consequent oxidative modification of cardiolipin, and defective assembly of respiratory supercomplexes. These adverse consequences of increased mitochondrial cholesterol trafficking trigger the onset of oxidative stress and cell death, and, ultimately, contribute to the development of diverse diseases, including metabolic liver diseases (i.e. fatty liver disease and liver cancer), as well as lysosomal disorders (i.e. Niemann-Pick type C disease) and neurodegenerative diseases (i.e. Alzheimer's disease). In this review, we summarize the metabolism and regulation of mitochondrial cholesterol and its potential impact on liver and neurodegenerative diseases., We acknowledge the support from grants PID2019-111669RB-100 and PID2020-115055RB-I00 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017- 1112, European Cooperation in Science & Technology (COST) ACTION CA17112, Prospective European Drug- Induced Liver Injury Network, the 2018-102799-T “Enfermedades Metabólicas y Cancer” from the Red Nacional of the Spanish Health Ministry and the Project 201916/31 Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3. In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

  • Gutiérrez, Alejandro H.
  • Mazariegos, Marina
  • Alemany, Susana
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Sanz-García, Carlos
The cytoplasmic protein tumor progression locus 2 (TPL2), also known as cancer Osaka thyroid (Cot), or MAP3K8, is thought to have a significant role in a variety of cancers and illnesses and it is a key component in the activation pathway for the expression of inflammatory mediators. Despite the tight connection between inflammation and TPL2, its function has not been extensively studied in chronic liver disease (CLD), a major cause of morbidity and mortality worldwide. Here, we analyze more in detail the significance of TPL2 in CLD to shed light on the pathological and molecular transduction pattern of TPL2 during the progression of CLD. This might result in important advancements and enable progress in the diagnosis and treatment of CLD., This work has received funding from the MICINN Retos PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2020-116146RB-I00 all of which were cofinanced with Fondos FEDER. The European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and COST Action CA17112. CSG is an Atracción de Talento (CAM) Researcher 2019-T1/BMD-13313., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

  • Martín-Adrados, Beatriz
  • Wculek, Stefanie K.
  • Fernández-Bravo, Sergio
  • Torres-Ruiz, Raúl
  • Valle-Noguera, Ana
  • Gómez-Sánchez, María José
  • Hernández-Walias, José Carlos
  • Moraes Ferreira, Frederico
  • Corraliza, Ana María
  • Sancho, David
  • Esteban, Vanesa
  • Rodríguez-Perales, Sandra
  • Cruz-Adalia, Aránzazu
  • Nakaya, Helder I.
  • Salas, Azucena
  • Bernardo, David
  • Campos-Martín, Yolanda
  • Martínez-Zamorano, Elena
  • Muñoz-López, Diego
  • Gómez del Moral, Manuel
  • Cubero, Francisco Javier
  • Blumberg, Richard S.
  • Martínez-Naves, Eduardo
[Introduction]: The Unfolded Protein Response, a mechanism triggered by the cell in response to Endoplasmic reticulum stress, is linked to inflammatory responses. Our aim was to identify novel Unfolded Protein Response-mechanisms that might be involved in triggering or perpetuating the inflammatory response carried out by the Intestinal Epithelial Cells in the context of Inflammatory Bowel Disease. [Methods]: We analyzed the transcriptional profile of human Intestinal Epithelial Cell lines treated with an Endoplasmic Reticulum stress inducer (thapsigargin) and/or proinflammatory stimuli. Several genes were further analyzed in colonic biopsies from Ulcerative Colitis patients and healthy controls. Lastly, we generated Caco-2 cells lacking HMGCS2 by CRISPR Cas-9 and analyzed the functional implications of its absence in Intestinal Epithelial Cells. [Results]: Exposure to a TLR ligand after thapsigargin treatment resulted in a powerful synergistic modulation of gene expression, which led us to identify new genes and pathways that could be involved in inflammatory responses linked to the Unfolded Protein Response. Key differentially expressed genes in the array also exhibited transcriptional alterations in colonic biopsies from active Ulcerative Colitis patients, including NKG2D ligands and the enzyme HMGCS2. Moreover, functional studies showed altered metabolic responses and epithelial barrier integrity in HMGCS2 deficient cell lines. [Conclusion]: We have identified new genes and pathways that are regulated by the Unfolded Protein Response in the context of Inflammatory Bowel Disease including HMGCS2, a gene involved in the metabolism of Short Chain Fatty Acids that may have an important role in intestinal inflammation linked to Endoplasmic Reticulum stress and the resolution of the epithelial damage., This work was supported by grants from Ministerio de Ciencia e Innovación (MCIN) from Spain [SAF2016-78711R and PID202-11794 to EM-N and FJC]; Comunidad de Madrid [B2017/BMD-3727 to EM-N and FJC]; Comunidad de Madrid (REACT-UE, ANTICIPA-CM Ref. PR38/21-24) to E.M-N and HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 to FJC the European Union’s Horizon 2020 research and innovation program [ERC-2016-Consolidator Grant 725091 to DS]; MCIN/AEI/10.13039/501100011033 [PID2019-108157RB to DS]; la Caixa Foundation (ID 100010434) [LCF/BQ/PR20/11770008 to SW]; Instituto de Salud Carlos III (ISCIII) [PI18/00348 to VE]; ISCIII [PI21/01641 to RT-R]; Spanish National Research and Development Plan, ISCIII and FEDER [PI17/02303 and PI20/01837 to SR-P]; Proyecto Desarrollo Tecnológico [DTS19/00111 to SR-P], AEI/MICIU EXPLORA Project [BIO2017-91272-EXP to SR-P]; Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485) [PID2019-104218RB-I00 to DB]; NIH [DK088199 to RB] and Universidad Complutense de Madrid (UCM 920631) [CT42/18-CT43/18 and EB15/21 to BM-A]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Zonal expression of StARD1 and oxidative stress in alcoholic-related liver disease

  • Fucho, Raquel
  • Solsona-Vilarrasa, Estel
  • Torres, Sandra
  • Nuñez, Susana
  • Insausti-Urkia, Naroa
  • Edo, Albert
  • Calvo, Maria V.
  • Bosch, Anna
  • Martin, Gemma
  • Enrich, Carlos
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Alcoholic-related liver disease (ALD) is one of the leading causes of chronic liver disease and morbidity. Unfortunately, the pathogenesis of ALD is still incompletely understood. StARD1 has emerged as a key player in other etiologies of chronic liver disease, and alcohol-induced liver injury exhibits zonal distribution. Here, we report that StARD1 is predominantly expressed in perivenous (PV) zone of liver sections from mice-fed chronic and acute-on-chronic ALD models compared to periportal (PP) area and is observed as early as 10 days of alcohol feeding. Ethanol and chemical hypoxia induced the expression of StARD1 in isolated primary mouse hepatocytes. The zonal-dependent expression of StARD1 resulted in the accumulation of cholesterol in mitochondria and increased lipid peroxidation in PV hepatocytes compared to PP hepatocytes, effects that were abrogated in PV hepatocytes upon hepatocyte-specific Stard1 KO mice. Transmission electron microscopy indicated differential glycogen and lipid droplets content between PP and PV areas, and alcohol feeding decreased glycogen content in both areas while increased lipid droplets content preferentially in PV zone. Moreover, transmission electron microscopy revealed that mitochondria from PV zone exhibited reduced length with respect to PP area, and alcohol feeding increased mitochondrial number, particularly, in PV zone. Extracellular flux analysis indicated lower maximal respiration and spared respiratory capacity in control PV hepatocytes that were reversed upon alcohol feeding. These findings reveal a differential morphology and functional activity of mitochondria between PP and PV hepatocytes following alcohol feeding and that StARD1 may play a key role in the zonal-dependent liver injury characteristic of ALD., We want to thank Eva Prats, Josep Manel Rebled, Rosa Rivera, Mora Gimeno, and Adriana Martínez from Transmission electron microscopy unit (TEM) for technical support. Carmen Garcia-Ruiz and Jose C Fernandez-Checa belong to the Spanish National Research Council's Cancer Hub. We acknowledge the support from grants PID2019-111669RB-100 and PID2020-115055RB-I00 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017-1112, European Cooperation in Science & Technology (COST) ACTION CA17112, Prospective European Drug-Induced Liver Injury Network, the 2018-102799-T “Enfermedades Metabólicas y Cancer” from the Red Nacional of the Spanish Health Ministry and the Project 201916/31 Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3, and the COVID grant from the Spanish Association for the Study of the Liver (AEEH). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary material to: Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
Supplementary methods, tables (1-4) and figures legends (1-10)., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

  • Marañón, Patricia
  • Rey, Esther
  • Isaza, Stephania C.
  • Wu, Hanghang
  • Rada, Patricia
  • Choya-Foces, Carmen
  • Martínez-Ruiz, Antonio
  • Martín, M. Ángeles
  • Ramos, Sonia
  • García-Monzón, Carmelo
  • Cubero, Francisco Javier
  • Valverde, Ángela M.
  • González-Rodríguez, Águeda
Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF., This study was supported by grants RTI2018-094203-B-I00 (to AMR), PID2020-11794RB-IOO (to FJC), PID2021-124688OB-I00 (to AMR) and PID2021-122766OB-100 (to AMV) and funded by MCIN/AEI/10.13039/501100011033 (Spain) and “ERDF A way of making Europe” by the European Union; the European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, funded by the European Union, and COST Action CA17112, supported by COST (European Cooperation in Science and Technology), to FJC, and contract CP19/00032, and grants PI16/00853 and PI19/00123 from Instituto de Salud Carlos III (ISCIII, Spain), partially funded by FEDER, and CIBERDEM (ISCIII, Spain) to AGR. FJC belongs to the validated Research Groups Ref. 970935 "Liver Pathophysiologÿ, 920631 "Lymphocyte immunobiologÿ, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). CCF is supported by grant FPU18/03475 from the Ministerio de Universidades (Spain), partially funded by FEDER. PMB is supported by a research contracts (PEJD-2018-PRE/BMD-9500PEJ-2020-AI/BMD-19491) funded by Comunidad de Madrid (Spain). SCI is supported by a predoctoral contract (FI20-00296) from ISCIII/FEDER (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cirrhosis-downregulated LSECtin can be retrieved by cytokines, shifts the TLR-induced LSECs secretome and correlates with the hepatic Th response

  • Martínez-López, Sebastián
  • Ángel-Gomis, Enrique
  • Gómez-Hurtado, Isabel
  • Fernández-Iglesias, Anabel
  • Morante, Javier
  • Gracia-Sancho, Jordi
  • Boix, Paula
  • Cubero, Francisco Javier
  • Zapater, Pedro
  • Caparrós, Esther
  • Francés, Rubén
[Background and aims]: We evaluated tolerogenic C-type lectin LSECtin loss in cirrhosis and its potential regulation by cytokines., [Methods]: Liver tissue from patients with cirrhosis and healthy controls, immortalised and generated LSECtin-CRISPR immortalised LSECs, and murine primary LSECs from the CCl4 model were handled., [Results]: LSECtin expression was reduced in liver tissue from cirrhotic patients, and it decreased from compensated to decompensated disease. Increased phosphorylation of MAPK, Akt and NFkB was observed upon LSECtin stimulation in LSEC murine cell line, showing a pattern of inflammatory and chemotactic cytokines either restrained (IL-10, CCL4) or unrestrained (TNF-α, IL-1β, IL-6, CCL2). CD44 attenuated whereas LAG-3 increased all substrates phosphorylation in combination with TLR4 and TLR2 ligands except for NFkB. TNF-α, IL-1 β, IL-6 and CCL2 were restrained by LSECtin crosslinking on TLRs studied. Conversely, IL-10 and CCL4 were upregulated, suggesting a LSECtin-TLRs synergistic effect. Also, LSECtin was significantly induced after IL-13 stimulation or combined with anti-inflammatory cytokines in cirrhotic and immortalised LSECs. Th17 and regulatory T cells were progressively increased in the hepatic tissue from compensated to decompensated patients. A significant inverse correlation was present between gene expression levels of CLEC4G/LSECtin and RORγT and FOXP3 in liver tissues., [Conclusion]: LSECtin restrains TLR proinflammatory secretome induced on LSECs by interfering immune response control, survival and MAPKs signalling pathways. The cytokine-dependent induction of LSECtin and the association between LSECtin loss and Th17 cell subset expansion in the liver, provides a solid background for exploring LSECtin retrieval as a mechanism to reprogram LSEC homeostatic function hampered during cirrhosis., This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-107036RB-I00 and PID2020-117941RB-I00, Instituto de Salud Carlos III PMP21/0082, PI20/00220 and DTS22/00010, EU Horizon-HLTH-2022-STAYHLTH-02 under agreement No. 101095679, Generalitat Valenciana Prometeo 2021/033, Comunidad de Madrid ExoHep2 S2022/BMD-7409 and AGAUR-Generalitat Catalunya (2021 SGR 01322 and 2021 PROD 00036). CIBEREHD is funded by the Instituto de Salud Carlos III using grants cofinanced by the European Development Regional Fund “A way to achieve Europe” (EDRF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  • Lucena, M. Isabel
  • Villanueva-Paz, M.
  • Álvarez-Álvarez, I.
  • Aithal, G. P.
  • Björnsson, E. S.
  • Cakan-Akdogan, G.
  • Cubero, Francisco Javier
  • Esteves, F.
  • Falcón-Pérez, Juan M.
  • Fromenty, B.
  • García-Ruiz, Carmen
  • Grove, J. I.
  • Konu, O.
  • Kranendonk, M.
  • Kullak-Ublick, G. A.
  • Miranda, Joana
  • Remesal-Doblado, A.
  • Sancho-Bru, P.
  • Nelson, L.
  • Andrade, Raúl J.
  • Daly, A. K.
  • Fernández-Checa, José C.
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

  • Goicoechea, Leire
  • Torres, Sandra
  • Fábrega Jiménez, Laura
  • Barrios, Mónica
  • Núñez, Susana
  • Casas, Josefina
  • Fabriàs, Gemma
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Niemann-Pick type C (NPC) disease is a lysosomal storage disorder characterized by impaired motor coordination due to neurological defects and cerebellar dysfunction caused by the accumulation of cholesterol in endolysosomes. Besides the increase in lysosomal cholesterol, mitochondria are also enriched in cholesterol, which leads to decreased membrane fluidity, impaired mitochondrial function and loss of GSH, and has been shown to contribute to the progression of NPC disease. S-Adenosyl-l-methionine (SAM) regulates membrane physical properties through the generation of phosphatidylcholine (PC) from phosphatidylethanolamine (PE) methylation and functions as a GSH precursor by providing cysteine in the transsulfuration pathway. However, the role of SAM in NPC disease has not been investigated. Here we report that Npc1-/- mice exhibit decreased brain SAM levels but unchanged S-adenosyl-l-homocysteine content and lower expression of Mat2a. Brain mitochondria from Npc1-/- mice display decreased mitochondrial GSH levels and liquid chromatography-high resolution mass spectrometry analysis reveal a lower PC/PE ratio in mitochondria, contributing to increased mitochondrial membrane order. In vivo treatment of Npc1-/- mice with SAM restores SAM levels in mitochondria, resulting in increased PC/PE ratio, mitochondrial membrane fluidity and subsequent replenishment of mitochondrial GSH levels. In vivo SAM treatment improves the decline of locomotor activity, increases Purkinje cell survival in the cerebellum and extends the average and maximal life spam of Npc1-/- mice. These findings identify SAM as a potential therapeutic approach for the treatment of NPC disease., Carmen Garcia-Ruiz and Jose C Fernandez-Checa belong to the Spanish National Researh Council's Cancer Hub. We are grateful for the support from grants PID2019-111669RB-100, PID2020-115055 R B-I00, PID2022-1429560B–I00 and 2023AEP068 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021-00491, European Cooperation in Science & Technology (COST) ACTION CA17112, Prospective European Drug- Induced Liver Injury Network, the 2018-102799-T “Enfermedades Metabólicas y Cancer” from the Red Nacional of the Spanish Health Ministry and the COVID grant from the Spanish Association for the Study of the Liver (AEEH). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and TOGETHER STRONG NPC FOUNDATION USA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholesterol's new tricks propel MASH-HCC: impact in immunotherapy

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network

  • Segovia-Zafra, Antonio
  • Villanueva-Paz, Marina
  • Serras, Ana Sofia
  • Matilla-Cabello, Gonzalo
  • Bodoque-García, Ana
  • Di Zeo-Sánchez, Daniel E.
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Sanz-Villanueva, Laura
  • Godec, Sergej
  • Milisav, Irina
  • Bagnaninchi, Pierre
  • Andrade, Raúl J.
  • Lucena, M Isabel
  • Fernández-Checa, José C.
  • Cubero, Francisco Javier
  • Miranda, Joana Paiva
  • Nelson, Leonard J.
Idiosyncratic drug-induced liver injury (DILI) is a complex and unpredictable event caused by drugs, and herbal or dietary supplements. Early identification of human hepatotoxicity at preclinical stages remains a major challenge, in which the selection of validated in vitro systems and test drugs has a significant impact. In this systematic review, we analyzed the compounds used in hepatotoxicity assays and established a list of DILI-positive and -negative control drugs for validation of in vitro models of DILI, supported by literature and clinical evidence and endorsed by an expert committee from the COST Action ProEuroDILI Network (CA17112)., This work was supported by grants from the Instituto de Salud Carlos III and Consejería de Salud de Andalucía, cofounded by Fondo Europeo de Desarrollo Regional (FEDER) (PI21/01248, PI19-00883, PT23/00137, PEMP-0127-2020, PI-0310-2018) and Agencia Española del Medicamento y Productos Sanitarios. M.V.P and I.A.A. hold Sara Borrell contracts (CD21/00198 and CD20/00083, respectively). H.N. holds a postdoctoral contract (POSTDOC_21_00780). A.S.Z. holds a Jaume Bosch predoctoral contract funded by CIBERehd (CECO-EHD002). D.D.S. holds an iPFIS predoctoral contract funded by ISCIII (IFI21/0034). G.M.C. holds an FPU PhD fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU22/03868). SCReN and CIBERehd are funded by ISCIII. A.S.S. holds a research scholarship funded by Fundação para a Ciência e a Tecnologia (2021.04902.BD). This publication is based on work from COST Action ‘CA17112 Prospective European Drug-Induced Liver Injury Network’ supported by COST (European Cooperation in Science and Technology); www.cost.eu. We acknowledge the support from grants PID2019-111669RB-100, PID2022-1429560B-I00 and PID2023AEP068 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI), FEDER and from the CIBEREHD; as well as funding by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679; UKRI Horizon Europe Grant 10067052, and support from AGAUR of the Generalitat de Catalunya SGR-2021-00491, and from the Project 201916/31 funded by Fundació Marató TV3. Funding for open access charge: Universidad de Málaga/CBUA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Palmitoylcarnitine impairs immunity in decompensated cirrhosis

  • Wei Zhang, Ingrid
  • Sánchez-Rodríguez, María Belén
  • López-Vicario, Cristina
  • Casulleras, Mireia
  • Duran-Güell, Marta
  • Flores-Costa, Roger
  • Aguilar, Ferran
  • Rothe, Michael
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trebicka, Jonel
  • Arroyo, Vicente
  • Clària, Joan
In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondrial dysfunction, are predictors of mortality in ACLF patients. Our hypothesis posits that acylcarnitines not only act as biomarkers, but also actively exert detrimental effects on circulating immune cells., Supported by the Plan Nacional de I+D funded by the Agencia Estatal de Investigación (grants PID2019-105240RB-I00 and PID2022-138970OB-I00 [to JC] and PID2019-111669RB-100 and PID2020-115055RB-I00 [to JCF-C]). JC laboratory is a Consolidated Research Group recognised by the Generalitat de Catalunya (2021 SGR 01323) and receives funds from EF CLIF and European Union’s Horizon 2020 research and innovation programme (MICROB-PREDICT [project ID 825694], DECISION [project ID 847949]). JCF-C receives funds from the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH, the Project 201916/31 by Fundació Marató TV3 and the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. JT is supported by the German Research Foundation project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research, the Arts for the ENABLE and ACLF-I cluster projects and the European Union’s Horizon 2020 research and innovation program for MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects. IWZ was supported by the Sheila Sherlock Post Graduate Programme of the European Association for the Study of the Liver., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Vallverdú, Julia
  • Xu, Zhenqing
  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Zanatto, Laura
  • Mercado-Gómez, Maria
  • Aguilar-Bravo, Beatriz
  • Ruiz-Blázquez, Paloma
  • Fernandez-Fernandez, Maria
  • Navarro-Gascon, Artur
  • Blasco-Roset, Albert
  • Sànchez-Fernàndez-de-Landa, Paula
  • Pera, Joan
  • Romero-Moya, Damia
  • Ayuso Garcia, Paula
  • Martínez Sánchez, Celia
  • Sererols Viñas, Laura
  • Cantallops Vilà, Paula
  • Cárcamo Giráldez, Carmen I.
  • McQuillin, Andrew
  • Morgan, Marsha Y.
  • Moya-Rull, Daniel
  • Montserrat, Núria
  • Eberlé, Delphine
  • Staels, Bart
  • Antoine, Bénédicte
  • Azkargorta, Mikel
  • Lozano, Juan-José
  • Martínez-Chantar, Maria L.
  • Giorgetti, Alessandra
  • Elortza, Félix
  • Planavila, Anna
  • Varela-Rey, Marta
  • Woodhoo, Ashwin
  • Zorzano, Antonio
  • Graupera, Isabel
  • Moles, Anna
  • Coll, Mar
  • Affo, Silvia
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs' commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease., P.S-B. is supported by Instituto de Salud Carlos III (ISCIII) “PI20/00765”, PI23/00724, “FORT23/00002”, “DTS22/00032”, AGAUR, “2021 PROD 00035”, 23-0356; Dissecting the role of the 14q32 region in hepatoblastoma “Hblast14” Worldwide Cancer Research; PRYCO223102ARME; Scientific Foundation of the Spanish Association Against Cancer (AECC); Q6922, (B-ORG) Plan Complementario de Biotecnología aplicada a la Salud del Plan de Recuperación, Transformación y Resiliencia. Ministerio de Ciencia e Innovación and co-founded the European research and innovation program Horizon HORIZON-HLTH−2022-STAYHLTH-02 under agreement no. 101095679. R.A M-G is funded by Instituto de Salud Carlos III “FI18/00215”, S.A. received a grant from the Ministerio de Educación, Cultura y Deporte “FPU17/04992”, C.M is funded by Centro de Investigación en Red Enfermedades Hepáticas y Digestivas (CIBERehd). A.G. is supported by Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/ Generalitat de Catalunya for institutional support. J.P. is supported by La Marató de TV3 (202001-32). D.R-M. is supported by Deutsche José Carreras Leukämie-Stiftung (DJCLS 13 R/2022). A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC 2016-19731; by Pfizer grant #77131383; P.R.B. was funded by Ministerio de Universidades fellowships FPU19/05357; M.F.F. was funded by FPU20/01367. M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/ AEI/10.13039/501100011033), Proyecto LABAECC2024 (funded by Asociación Española Contra el Cáncer, AECC), HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). This study was funded by Instituto de Salud Carlos III through the Biobanks and Biomodels Platform and co‐funded by the European Union (PTC20/00013, PT20/00130, PT23/00009 and PTC23/00002 to N.M.) and by Instituto de Salud Carlos III and European Union—Next Generation EU, Plan de Recuperación Transformación y Resiliencia (TERAV/ISCIII RD21/0017/0018) to N.M; M.C. was funded by Ramon y Cajal programme from the Ministerio de Ciencia e Innovación RYC2019-026662-I. S.A. is funded by la Caixa Foundation “100010434” and the European Union’s Horizon 2020 under the Marie Skłodowska-Curie “847648”, PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312*. Ramon y Cajal program RYC2022-036321-I. (* Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bile acids in liver and gastrointestinal cancer

  • Monte, Maria J.
  • Fàbrega, Laura
  • Romero, Marta R.
  • Temprano, Alvaro G.
  • Kaplowitz, Neil
  • García-Ruiz, Carmen
  • Marin, Jose J. G.
  • Fernández-Checa, José C.
Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer., We acknowledge the support from grants PID2019-111669RB-100, PID2020-115055RB-I00, PID2022-142956OB-100, PID2022-140210OB-100, PID2023-1488030B-100, 2024AEP053; 2023AEPP068 and 2020AEPP145 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI); Plan Nacional sobre Drogas grant 2024; and PI22/00526 from the Fondo de Investigaciones Sanitarias, Instituto Salud Carlos III, Spain co-funded by European Regional Development Fund/European Social Fund, Junta Castilla y Leon (SA113/P23) and from the CIBEREHD; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021–00491, and funding from the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, as well as support from National Cancer Institute PO1 CA281819–01A1 from the NIH. L.F. is supported by a Jaume Bosch contract from the CIBEREHD, and she is a PhD student of the Biomedicine Program of the University of Barcelona, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

  • Cardoso Delgado, Teresa de Jesús
  • Martín-Cuevas, Celia
  • Sánchez-Hidalgo, Ana C.
  • Gil-Gómez, Antonio
  • Rejano-Gordillo, Claudia María
  • Landa, Jon
  • Gallego-Durán, Rocío
  • Goikoetxea-Usandizaga, Naroa
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Zapata-Pavas, L. Estefanía
  • Barrenechea-Barrenechea, Jon Ander
  • Conter, Carolina
  • Martínez-Cruz, Luis Alfonso
  • Ramos Herrero, Víctor
  • Nogueiras, Rubén
  • Azkargorta, Mikel
  • Elortza, Félix
  • Moncho-Amor, Verónica
  • Crespo, Javier
  • Matheu, Ander
  • Romero-Gómez, Manuel
  • Crespo-Facorro, Benedicto
  • Martínez-Chantar, María Luz
[Data and materials availability:] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD063321 (www.ebi.ac.uk/pride/archive/projects/PXD063321). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials., Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N-acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA-Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: CEX2021-001136-S (to M.L.M.-C.) and MICINN: PID2022-139395OB-100 (to M.L.M.-C.); integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER; and Project funded by CIBEREHD; 2018 BBVA Foundation Grants for Scientific Research Teams- UMBRELLA (to M.L.M.-C., M.R.G., and B.C.-F.). T.C.D. is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu futuro.” This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116OB-I00 (to T.C.D.). C.M.-C. was supported by CIBERSAM (G26) and the Instituto de Salud Carlos III (AC23_2/00034). A.C.S.H. received funding from CIBERSAM (G26) and the Consejería de Salud y Familias (RH-0063). V.D.R.H. was supported by the Agencia Estatal de Investigación (PID2019-109405R and PI-0014-2022). L.E.Z.-P. was supported by a PhD fellowship from the Provincial Section of Bizkaia from the Scientific Foundation of the Spanish Association Against Cancer PRDVZ233980ZAPA. C.M.R.G. was supported by Ayuda Juan de la Cierva JDC2023-052761-I from the MCIN/AEI/10.13039/501100011033–Unión Europea NextGenerationEU/PRTR. V.M.-A. was supported by the Miguel Servet contract (CP23/00111) from the ISCIII. This project has also received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 (agreement no. 101095679), Spanish Instituto de Salud Carlos III-FEDER Grant (FIS-PI22/01853) and European Union-NextGenerationEU (PMP21/00112) (to J.C.)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of SREBF2 and HMGCR discriminates the viability of steatotic grafts for human liver transplantation

  • Baulies, Anna
  • Torres, Sandra
  • Fucho, Raquel
  • Nuñez, Susana
  • Torres, Ferrán
  • Ferrer, Joana
  • Díaz, Alba
  • Rico, Naira
  • García-Valdecasas, Juan Carlos
  • Fuster, Josep
  • Adalia, Ramón
  • Paredes, David
  • Rimola, Antoni
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
We acknowledge the support from the grants Fundación Mutua Madrileña; grants PID2022-142956OB-100, PID2022-140169OB-C22 and PID2023-148803OB-100 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as support from National Cancer Institute PO1 CA281819-01A1 from the NIH; AGAUR of the Generalitat de Catalunya SGR-2021-00491; ST holds a Ramón y Cajal fellowship (RYC2023-042649-I), and has received research support from the CIBEREHD intramural project 2023 (EHD25PI01). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacterial metabolic signatures in MASLD predicted through gene-centric studies in stool metagenomes

  • Medina, Juan M.
  • Iruzubieta, Paula
  • Fernández-López, Raúl
  • Crespo, Javier
  • Cruz, Fernando de la
[Background] Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multifactorial condition in which the gut microbiome (GM) plays a central role. However, taxonomic associations derived from 16S ribosomal RNA (rRNA) gene studies have yielded inconsistent results, likely due to limited resolution and functional redundancy across taxa. We aimed to identify robust, functionally relevant microbial markers of MASLD using metagenomics and gene-centric profiling., [Methods] We analyzed 554 fecal metagenomes from three independent cohorts. Sequencing reads were quality-controlled and taxonomically profiled with multi-marker gene resolution. We quantified the abundance of over 50 target gene families involved in butyrate, methane, trimethylamine (TMA) and short-chain alcohol (SCAs, i.e., ethanol and propanol) metabolism. Their presence was also determined across complete GM genomes and plasmids., [Results] Genes involved in butyrate and methane production tended to show lower abundance in MASLD, particularly in cirrhosis, while TMA- and SCA-producing genes were frequently enriched. These functional shifts were accompanied by the depletion of Agathobacter rectalis. Many of the altered genes were highly accessory and encoded on plasmids, suggesting genome-specific functional divergence driven by horizontal gene transfer., [Conclusion] MASLD is characterized by a shift toward alcohol- and TMA-producing metabolism, alongside reduced butyrate and methane production -changes driven by accessory and plasmid-borne genes. Gene-centric and mobile genetic element-aware profiling reveals mechanistic microbial contributions to MASLD that remain undetected by taxonomy-based approaches, offering new targets for diagnosis and intervention., This work was funded by grant PID2020-1179236B-100 from the Spanish MINECO, grant PI22/01853 from the Spanish Carlos III Health Institute (ISCIII) and by HORIZON-HLTH-2022-STAYHLTH-02 (agreement No. 101095679) from the European Horizon’s research and innovation program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids

  • Menacho, Carmen
  • Okawa, Satoshi
  • Álvarez-Merz, Iris
  • Wittich, Annika
  • Muñoz-Oreja, Mikel
  • Lisowski, Pawel
  • López Martín, Mario
  • Pentimalli, Tancredi Massimo
  • Zakin, Shiri
  • Thevandavakkam, Mathuravani
  • Jerred, Caleb
  • Lickfett, Selene
  • Petersilie, Laura
  • Rybak-Wolf, Agnieszka
  • Seibt, Annette
  • Herebian, Diran
  • Inak, Gizem
  • Brodesser, Susanne
  • Zaliani, Andrea
  • Mlody, Barbara
  • Donnelly, Justin
  • Woleben, Kasey
  • Soriano, Francesc Xavier
  • Fernández-Checa, José C.
  • Ventura, Natascia
  • Cambridge, Sidney
  • Mayatepek, Ertan
  • Spinazzola, Antonella
  • Schuelke, Markus
  • Rajewsky, Nikolaus
  • Rossi, Andrea
  • Peralvarez-Marin, Alex
  • Distelmaier, Felix
  • Perlstein, Ethan
  • Holt, Ian J.
  • Puighermanal, Emma
  • Pless, Ole
  • Rose, Christine R.
  • Del Sol, Antonio
  • Prigione, Alessandro
Leigh syndrome (Leigh) is an untreatable mitochondrial disorder characterized by lactic acidosis and basal ganglia and midbrain pathology, leading to psychomotor regression and early death. We previously uncovered impaired neuronal morphogenesis in Leigh cerebral organoids carrying SURF1 gene variants. Leveraging this phenotype, we here develop a deep learning algorithm tailored for cell type-specific drug repurposing screening. In parallel, we perform a survival drug screen in a yeast model of Leigh. The two approaches independently converge on azole compounds, two of which - talarozole and sertaconazole - rescue neuronal morphogenesis in Leigh neurons and lower lactate release and improve growth rate in Leigh midbrain organoids. Mechanistically, these compounds modulate the retinoic acid pathway and membrane-associate lipid metabolism. The findings highlight azoles as promising candidates for Leigh and demonstrate the potential of combining in silico screens with human brain organoids as new approach methodologies (NAMs) to advance the discovery of therapeutics addressing rare neurodevelopmental disorders., Open Access funding enabled and organized by Projekt DEAL. We thank Jens Schwamborn (Luxembourg University) and his group for providing their published MO datasets. We acknowledge support from the Deutsche Forschungsgemeinschaft (DFG) (PR1527/5-1, PR1527/6-1, PR1527/15-1, PR1527/14-1, and PR1527/13-1 to A.P.; RO5380/1-1 to A.R.; Ro2327/13-2 to C.R.R.; AL2956/1-1 to I.A-M.; VE366/12-1 to N.V.), the European Joint Programme on Rare Diseases (EJP RD) and Federal Ministry of Research, Technology and Space (BMFTR) (CureMILS #01GM2002A to A.P., #01GM2002B to O.P.), the Medical Faculty of Heinrich Heine University (FoKo grant to A.P. and S.C.), the European Commission’s Horizon Europe Programme (SIMPATHIC #101080249 to A.P. and M.S.), AFM-Téléthon (SildeMITO #28545 to A.P. and M.S.; GenT-Leigh #29044 to A.P.), the United Mitochondrial Disease Foundation (UMDF) and the Leigh Syndrome International Consortium (LSIC) (to A.P.), People Against Leigh syndrome (PALS) (to A.P.), the Foundation Maladies Rare and Association (AMMi) (to A.P.), the patient organizations Mitocon, Cure Mito, Cure ATP6, Mito Foundation, and MitoHelp (to A.P.), and the Eva Luise Köhler Foundation (to A.P. and M.S.), the Studienstiftung des deutschen Volkes (to S.L.), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGUAR) Generalitat de Catalunya through the Indústria del Coneixement LLAVOR program (grant 2024 LLAV 00069 to E.Pu.), National Science Center OPUS (#2017/27/B/NZ1/02401 to P.L.), and funds from MICINN (PID2021-125079OA-I00 to E.Pu.). A.Sp. and I.J.H. receive research support from the UK Medical Research Council (MR/X002365/1), Muscular Dystrophy UK (17GRO-PG24-0184-1), and the CHAMP Foundation. A.Sp. is the recipient of a Miriam Marks Senior Fellowship, Brain Research UK (202021-26) and receives funds from the Lily Foundation. I.J.H. is supported by grants from the Instituto de Salud Carlos III PI20/00096, the Spanish Ministry of Science, PID2023-151649NB-I00, and the Basque Government Department of Health (Osasun Saila, Eusko Jaurlaritzako) (grants 2021111070; 2022333050; 2018111043; 2018222031). M.M.O. was partially supported by the Ikerbasque, Basque Foundation for Science IKUR strategy, Neurodegenprot project. S.L. was supported by the Studienstiftung des deutschen Volkes. J.F-C acknowledges support from the MICINN (PID2022-142956OB-100 and PID2025-173094OB-I00), the National Cancer Institute PO1 CA281819-O1A1 from the NIH, and the CIBEREHD and the European Horizon´s research and Innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement #101095679). We are grateful to Anje Sporbert (Advanced Light Microscopy, MDC, Berlin) for help with the mitochondrial movement recordings and acknowledge the Center for Advanced Imaging (CAi) at Heinrich Heine University Düsseldorf for providing access to the PerkinElmer Operetta CLS (DFG grant # INST 208/760-1 FUGG) and Olympus FV3000 microscope., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Cholesterol metabolic reprogramming in alcohol associated liver disease

  • Barrios, Mónica
  • Torres, Sandra
  • Fàbrega, Laura
  • Nuñez, Susana
  • Fucho, Raquel
  • Solsona-Vilarrasa, Estel
  • Rico, Naira
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Trabajo presentado en el ASBMB Annual Meeting (2026), celebrado en Washington, D.C.(Estado Unidos), del 7 al 10 de marzo de 2026, We acknowledge the support from the grants PID2023-148803OB-I00, PID2022-142956OB-I00 and PID2022-140169OB-C22 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as “Plan Nacional sobre Drogas” 2024 from the Ministry of Health, and support from AGAUR of the Generalitat de Catalunya SGR-2021-00491; CIBEREHD intramural project grant for junior researchers 2023; European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug- Induced Liver Injury Network. National Cancer Institute PO1 CA281819-01A1 from the NIH; Beatriu de Pinós Post-doctoral grant (2021 BP00187); and from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. ST holds a Ramón y Cajal fellowship (RYC2023-042649-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease

  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Serrano, Guillermo
  • Zanatto, Laura
  • Martínez-García de la Torre, Raquel A.
  • Gratacós-Ginès, Jordi
  • Rubio, Ana Belén
  • Pérez, Martina
  • Mateos-Sánchez, Carlos
  • Aguilar-Bravo, Beatriz
  • Atkinson, Stephen
  • Xu, Zhengqing
  • Cantallops-Vilà, Paula
  • Sererols-Viñas, Laura
  • Ruiz-Blázquez, Paloma
  • Rill, Aina
  • Fundora, Yiliam
  • Lozano, Juan José
  • Coll, Mar
  • Ochoa, Idoia
  • Affo, Silvia
  • Moles, Anna
  • Mereu, Elisabetta
  • Bataller, Ramón
  • Pose, Elisa
  • Sancho-Bru, Pau
Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD., This work has been supported by grants to P.S-B. Proyecto PI20/00765 and PI23/00724, funded by “Instituto de Salud Carlos III (ISCIII) co-financed by the European Union. By HORIZON-HLTH-2022- STAYHLTH-02, grant number 101095679, funded by the European Union. Project FORT23/00002, funded by Instituto de Salud Carlos III (ISCIII) "Programa FORTALECE del Ministerio de Ciencia, Innovación y Universidades". This work has also been co-financed for P.S-B by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR-C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health (Q6922). S.A. received a fellowship from the Ministerio de Educación, Cultura y Deporte (FPU17/04992). R.A. M-G. was funded by the Instituto de Salud Carlos III, PFIS (FI18/00215). B.A-B. was funded by Instituto de Salud Carlos III, PFIS (FI16/00203). M.C. is funded by the Ramon y Cajal program from the Ministerio de Ciencia e Innovación RYC2019-026662-I and by the State Plan of Scientific and Technical Research and Innovation PID2021-125195OB-I00. S.A. is funded by the MCIN/AEI/10.13039/501100011033 by “ERDF A way of making Europe” (PID2021-124694OA-I00) and the European Union grant agreement 101077312. A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033; by Pfizer grant #77131383; and the contract RYC-2016-19731. P.R-B received a fellowship from the Spanish Ministry of Education, Culture and Sports, FPU program (FPU19/05357)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prenols and prenoic acids in metabolism, disease, and aging

  • Verdaguer, Ignasi Bofill
  • Hernández, Agustín
  • Torres, Sandra
  • Rodríguez-Peiris, Maria
  • Arenas, Fabian
  • Martinez, Damelia Echevarria
  • López, Monica Barrios
  • Crispim, Marcell
  • Tabata, Yuki
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Acyclic terpene derivatives are well-known as components of plant essential oils and insect hormones, yet their active biosynthesis also occurs in mammals. The terpenic alcohols-or prenols-geranylgeraniol (GGOH) and farnesol (FOH), together with their prenoic acids and derivatives, were identified in mammalian cells over 60 years ago but remain largely overlooked. These metabolites display diverse biological functions: they induce autophagy, inhibit tumor growth and inflammation, suppress cholesterol synthesis, enhance insulin sensitivity and cognition, regulate sexual characteristics, and promote healthy aging. In mammals, prenols arise from an age-dependent, bidirectional pathway that interconverts polyprenyl diphosphates, prenols, and prenoic acids. They can be oxidized into aldehydes and carboxylic acids or reconverted into diphosphate forms for use in protein prenylation and in the biosynthesis of ubiquinone, cholesterol, and dolichol. Although enzymes catalyzing polyprenyl diphosphate dephosphorylation and oxidation steps have been partly characterized, the kinases mediating their reverse phosphorylation remain unidentified. This review summarizes current advances in the understanding of prenol metabolism in mammals, emphasizing its role in metabolic regulation, disease prevention, and longevity. By integrating biochemical and physiological evidence, we highlight the emerging view that these small terpenes constitute a fundamental yet underexplored layer of metabolic control. Greater attention to this pathway may reveal novel strategies for maintaining metabolic health and mitigating age-related disorders., I. B. V. is fellow from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); I. B. V. FAPESP process number: 2022/09526-4. M. C. was supported by a Beatriu de Pinós fellowship from AGAUR (Government of Catalonia). This work received support from the grants PID2022-142956OB-100, PID2022-140169OB-C22, and PID2023-148803OB-100 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as support from National Cancer Institute PO1 CA281819-01A1 from the NIH, and from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed